NASDAQ:CLSN - Celsion Stock Price, Forecast & News

Celsion trades on the NASDAQ under the ticker symbol "CLSN."

Celsion's stock reverse split before market open on Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 26th 2017. An investor that had 100 shares of Celsion stock prior to the reverse split would have 7 shares after the split.

Celsion Co. (NASDAQ:CLSN) issued its earnings results on Friday, November, 15th. The biotechnology company reported ($0.25) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.05. The biotechnology company earned $0.13 million during the quarter, compared to analyst estimates of $0.13 million. Celsion had a negative net margin of 1,653.20% and a negative return on equity of 57.46%. View Celsion's Earnings History.

Celsion is scheduled to release their next quarterly earnings announcement on Friday, April 3rd 2020. View Earnings Estimates for Celsion.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Celsion.

News articles about CLSN stock have trended negative recently, InfoTrie Sentiment reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Celsion earned a daily sentiment score of -2.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Celsion.

Some companies that are related to Celsion include Corvus Pharmaceuticals (CRVS), American Brivision (Holding) (ABVC), ProMetic Life Sciences (PFSCF), Sesen Bio (SESN), Proteostasis Therapeutics (PTI), CELYAD SA/ADR (CYAD), Agile Therapeutics (AGRX), AVEO Pharmaceuticals (AVEO), Tyme Technologies (TYME), OASMIA PHARMACE/ADR (OASM), NeuBase Therapeutics (NBSE), CymaBay Therapeutics (CBAY), BioXcel Therapeutics (BTAI), Axovant Gene Therapies (AXGT) and CytoDyn (CYDY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Agenus (AGEN), Synergy Pharmaceuticals (SGYP), Rexahn Pharmaceuticals (REXN), Inovio Pharmaceuticals (INO), BIOLINERX LTD/S (BLRX), Novavax (NVAX), Amarin (AMRN), NovaBay Pharmaceuticals (NBY), Tesla (TSLA) and Viking Therapeutics (VKTX).

Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CLSN stock can currently be purchased for approximately $1.45.

Celsion has a market capitalization of $33.00 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-11,880,000.00 in net income (profit) each year or ($0.68) on an earnings per share basis. Celsion employs 29 workers across the globe.View Additional Information About Celsion.

The official website for Celsion is http://www.celsion.com/.

Celsion's mailing address is 997 LENOX DRIVE SUITE 100, LAWRENCEVILLE NJ, 08648. The biotechnology company can be reached via phone at 609-896-9100 or via email at [email protected]